Zentalis Pharmaceuticals (ZNTL) Competitors $1.66 +0.06 (+3.42%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. RAPT, OCGN, LRMR, ALMS, AUTL, ETHZ, ATXS, ADCT, PRTC, and FDMTShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Rapt Therapeutics (RAPT), Ocugen (OCGN), Larimar Therapeutics (LRMR), Alumis (ALMS), Autolus Therapeutics (AUTL), Flag Ship Acquisition (ETHZ), Astria Therapeutics (ATXS), ADC Therapeutics (ADCT), PureTech Health (PRTC), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors Rapt Therapeutics Ocugen Larimar Therapeutics Alumis Autolus Therapeutics Flag Ship Acquisition Astria Therapeutics ADC Therapeutics PureTech Health 4D Molecular Therapeutics Rapt Therapeutics (NASDAQ:RAPT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Do analysts prefer RAPT or ZNTL? Rapt Therapeutics presently has a consensus price target of $23.50, indicating a potential downside of 24.96%. Zentalis Pharmaceuticals has a consensus price target of $5.84, indicating a potential upside of 250.75%. Given Zentalis Pharmaceuticals' higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Rapt Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.55Zentalis Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33 Does the media refer more to RAPT or ZNTL? In the previous week, Rapt Therapeutics had 4 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 5 mentions for Rapt Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Rapt Therapeutics' average media sentiment score of 0.12 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Rapt Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapt Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, RAPT or ZNTL? Rapt Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt Therapeutics$1.53M338.53-$129.87M-$14.17-2.21Zentalis Pharmaceuticals$67.43M1.78-$165.84M-$2.26-0.74 Which has more volatility and risk, RAPT or ZNTL? Rapt Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Is RAPT or ZNTL more profitable? Zentalis Pharmaceuticals' return on equity of -51.62% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -67.92% -59.59% Zentalis Pharmaceuticals N/A -51.62%-40.28% Do institutionals and insiders believe in RAPT or ZNTL? 99.1% of Rapt Therapeutics shares are held by institutional investors. 6.6% of Rapt Therapeutics shares are held by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryRapt Therapeutics beats Zentalis Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.83M$3.36B$6.13B$10.57BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-0.7422.1086.7226.98Price / Sales1.78267.67535.32203.83Price / CashN/A46.3226.3031.11Price / Book0.359.9412.756.63Net Income-$165.84M-$52.35M$3.30B$276.05M7 Day Performance11.74%5.68%3.98%2.73%1 Month Performance-4.86%11.29%7.28%10.11%1 Year Performance-50.59%25.44%74.23%33.16% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.4637 of 5 stars$1.67+3.4%$5.84+250.8%-52.2%$120.83M$67.43M-0.74160Positive NewsRAPTRapt Therapeutics3.5026 of 5 stars$26.62+0.9%$23.50-11.7%+88.4%$436.27M$1.53M-1.8880High Trading VolumeOCGNOcugen1.7184 of 5 stars$1.45-0.7%$6.00+313.8%+75.2%$426.77M$4.05M-7.2580Positive NewsLRMRLarimar Therapeutics2.9924 of 5 stars$3.38-33.6%$18.43+445.2%-26.8%$421.75MN/A-2.1730High Trading VolumeALMSAlumis3.6266 of 5 stars$3.95-2.5%$20.17+410.5%-58.7%$421.46MN/A0.00N/ANews CoverageAUTLAutolus Therapeutics3.564 of 5 stars$1.59+1.9%$9.12+473.6%-59.5%$415.18M$10.12M-1.89330ETHZFlag Ship AcquisitionN/A$2.48-1.2%N/AN/A$412.72MN/A-0.167ATXSAstria Therapeutics2.6419 of 5 stars$7.36+0.8%$30.20+310.3%-36.6%$411.98MN/A-3.6630Positive NewsADCTADC Therapeutics2.93 of 5 stars$4.02+10.0%$7.75+93.0%+24.7%$410.62M$70.84M-2.56310News CoveragePositive NewsAnalyst RevisionGap UpPRTCPureTech Health0.0718 of 5 stars$18.15+7.4%N/A-6.6%$408.45M$4.83M0.00100Positive NewsGap UpFDMT4D Molecular Therapeutics2.5331 of 5 stars$8.35-0.5%$30.40+264.1%-14.2%$391.83M$40K-2.37120 Related Companies and Tools Related Companies RAPT Competitors OCGN Competitors LRMR Competitors ALMS Competitors AUTL Competitors ETHZ Competitors ATXS Competitors ADCT Competitors PRTC Competitors FDMT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthGovernment Gridlock – The Final Act in a Collapse Trump's extension of this wealth saving loophole may be y...American Hartford Gold | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
